Rich Pharmaceuticals Inc. (fka RCHA)

[cjstocksup]

RCHA and WX connections below:
WuXi PharmaTech, Inc. trades on the NYSE in the area of $46.00 per share under the ticker of WX with a $2.8 Billion Market Cap:
(This info is old from 2015 on the WuXi numbers so they could be much higher today!)

http://finance.yahoo.com/q/ks?s=WX+Key+Statistics
http://finance.yahoo.com/q?s=wx&ql=1
http://www.wuxiapptec.com/



"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110569310


RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide.

Business Overview

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free.
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ).

Market Opportunities

AML

It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:

Key RCHA & WX:NYSE Relationship
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110555124

RCHA NEWS

http://finance.yahoo.com/q/h?s=RCHA+Headlines
http://www.richpharmaceuticals.com/category/news/

RCHA SEC FILINGS
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001504389&owner=exclude&count=40

http://www.richpharmaceuticals.com/contact-us/

Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045
P: 424.230.7001
F: 424.230.7003
E: [e-mail]